Dear Visitor,

The independent, prospective, multicenter clinical study in mesangial IgA glomerulonephritis ( CLIgAN), also referred to as Berger's disease , evaluates the effect of personalized therapy that is given to patients within 2 to 4 weeks following a kidney biopsy.
The project, called BIO-D, was funded by the Ministry of the University ( ARS01_00876 ) and by the Schena Foundation, the European Center for the Study of Kidney Diseases. The CLIgAN study, authorized by the Italian Medicines Agency (AIFA), was registered on the international website ClinicalTrial.gov (NCT 04662723) and on the European website (EudraCT:2021-006854-29).
In order to improve collaboration between the study partners and to disseminate the final results, the Scientific Committee has deemed it appropriate to develop three sites with different uses and destinations.
The first site https://igan.ba.infn.it , used in the past for other funded projects on IgA nephropathy, has the task of communicating news on the progress of the CLIgAN study to all participants. Partners can consult the site to see the technical and clinical updates on the study that are communicated and illustrated every six month.
The second site https://bio-d.ba.infn.it/Omniacare-Nefrologia , contains the electronic medical record, called Case Report Form (eCRF), which collects the anamnestic information, the physical examination and the laboratory tests of each patient collected during the different phases of the study. It is used by all study partners.
Finally, there is a third site https://igan.kidney boibsy.infn.it which contains all the high-definition images of the kidney biopsies used by pathologists for the CLIgAN study.
At the conclusion of this brief illustration of the study, the Scientific Committee of the CLIgAN study wishes to thank, in particular, the patients who have joined the study because we hope that this clinical contribution, provided by all project partners, will improve the clinical course of the disease.